Skip to main
LH

LH Stock Forecast & Price Target

LH Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Labcorp Holdings has demonstrated robust revenue growth, with the Central Lab segment achieving a remarkable $554.7 million in revenue, reflecting a 7.5% increase driven by significant trial wins and the incorporation of digital pathology capabilities. The Diagnostic segment also continues to perform well, reporting $2.75 billion in revenue, which represents an 8.9% year-over-year increase, supported by both organic growth and acquisitions. Additionally, the company exhibits a strong order backlog of $8.71 billion, which is up approximately 10% year-over-year, coupled with a trailing twelve-month net book-to-bill ratio of 1.11x, indicating continued positive momentum in demand for its services.

Bears say

The analysis highlights several fundamental risks contributing to a negative outlook on Labcorp Holdings' stock. Key concerns include potential adverse shifts in reimbursement policies, challenges related to the integration of acquisitions, and escalating competition within the clinical laboratory market. Additionally, ongoing economic uncertainty coupled with potential regulatory challenges further threatens the company's financial stability and future performance.

LH has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Labcorp Holdings Inc (LH) Forecast

Analysts have given LH a Buy based on their latest research and market trends.

According to 12 analysts, LH has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $301.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $301.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Labcorp Holdings Inc (LH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.